Walleye Capital
ALNY icon

Walleye Capital’s Alnylam Pharmaceuticals ALNY Stock Holding History

Walleye Capital’s Portfolio ALNY Stock Details ALNY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.19M Buy
3,600
+800
+29% +$272K 0.01% 1918
2025
Q4 		$1.11M Buy
2,800
+2,200
+367% +$974K ﹤0.01% 2347
2025
Q3 		$274K Sell
600
-700
-54% -$285K ﹤0.01% 3089
2025
Q2 		$424K Sell
1,300
-1,100
-46% -$304K ﹤0.01% 2772
2025
Q1 		$648K Sell
2,400
-4,000
-63% -$1.03M ﹤0.01% 2338
2024
Q4 		$1.51M Sell
6,400
-9,000
-58% -$2.37M ﹤0.01% 2038
2024
Q3 		$4.24M Buy
15,400
+14,900
+2,980% +$3.88M 0.01% 1303
2024
Q2 		$122K Sell
500
-4,900
-91% -$774K ﹤0.01% 4621
2024
Q1 		$807K Buy
5,400
+2,700
+100% +$450K ﹤0.01% 2788
2023
Q4 		$517K Sell
2,700
-6,800
-72% -$1.16M ﹤0.01% 2925
2023
Q3 		$1.68M Buy
9,500
+7,300
+332% +$1.39M ﹤0.01% 1864
2023
Q2 		$418K Sell
2,200
-5,100
-70% -$1.01M ﹤0.01% 2563
2023
Q1 		$1.46M Buy
7,300
+7,000
+2,333% +$1.47M 0.02% 904
2022
Q4 		$71.3K Buy
+300
New +$64K ﹤0.01% 2453
2020
Q1 		– Sell
-5,700
Closed -$656K – 871
2019
Q4 		$656K Buy
5,700
+4,800
+533% +$479K 0.04% 567
2019
Q3 		$72K Sell
900
-13,300
-94% -$1.05M ﹤0.01% 1507
2019
Q2 		$1.03M Buy
14,200
+5,000
+54% +$384K 0.11% 257
2019
Q1 		$860K Buy
+9,200
New +$769K 0.14% 214

Other funds holding ALNY

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Capital Research Global Investors
Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return
VPM
Vanguard Portfolio Management Malvern, Pennsylvania $1.91T AUM
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Walleye Capital's ALNY Position: Q1 2026 in Review

Walleye Capital reduced its Alnylam Pharmaceuticals (ALNY) stake by 56% in Q1 2026, selling an estimated $1.13M and leaving 2,639 shares worth $873K. The position accounts for ﹤0.01% of the portfolio, ranked #2201.

Walleye Capital first reported a position in ALNY in Q3 2018 and has held it in 15 quarters since. The position peaked at $17.1M in Q2 2024. 786 funds tracked by Wall St. Rank hold ALNY as of Q1 2026.

  • Walleye Capital held 2,639 shares of Alnylam Pharmaceuticals worth $873K as of Q1 2026.
  • Walleye Capital sold 3,329 Alnylam Pharmaceuticals shares in Q1 2026, an estimated $1.13M.
  • Alnylam Pharmaceuticals made up ﹤0.01% of Walleye Capital's portfolio in Q1 2026, its #2201 holding.
  • Walleye Capital first reported a position in Alnylam Pharmaceuticals in Q3 2018 and has held it in 15 quarters since.
  • Walleye Capital's Alnylam Pharmaceuticals position peaked at $17.1M in Q2 2024.
  • 786 funds tracked by Wall St. Rank held Alnylam Pharmaceuticals as of Q1 2026.

Based on Walleye Capital's 13F filing for Q1 2026, filed 11 May 2026.